Windlas Biotech reports record Rs 904 crore revenue for FY26 with 19% growth

Business Desk — Thu, 21 May 2026 12:04:24 +0000

Windlas Biotech Limited, a prominent player in the Indian pharmaceutical formulations contract development and manufacturing organisation (CDMO) industry, has reported a record revenue of ₹904 crore for the financial year ending March 31, 2026. This marks a 19% increase compared to the previous year.

For the fourth quarter of FY26, the company achieved a revenue of ₹238 crore, reflecting an 18% year-on-year growth. The company’s adjusted EBITDA for FY26 stood at ₹121 crore, a 26% increase from the previous year, with an adjusted EBITDA margin of 13.4%. The adjusted profit after tax (PAT) rose by 31% to ₹83 crore, with a PAT margin of 9.2%.

In the CDMO vertical, Windlas Biotech reported revenue of ₹664 crore for FY26, up 20% year-on-year, contributing approximately 73% to the consolidated revenue. The Trade Generics & Institutional vertical saw a 13% increase in revenue to ₹195 crore, while the Exports vertical grew by 40% to ₹46 crore.

Hitesh Windlass, Managing Director of Windlas Biotech, highlighted the company’s focus on scalability and profitability, stating that the business generated ₹105 crore of net operating cash flows, closing the year with a strong net liquidity position of ₹251 crore. He also noted the strategic investments in their facilities, with Plant-4 and Plant-5 receiving GMP certification from the Philippines, and Plant-6 on track for commercialisation by the first half of FY27.

Komal Gupta, CEO & CFO of Windlas Biotech, emphasised the company’s consistent growth despite a dynamic operating environment. She pointed out that the company achieved 13 consecutive quarters of record revenue, with a significant contribution from the Generic Formulations CDMO vertical.

Looking forward, Windlas Biotech aims to enhance long-term shareholder value by diversifying its client base, increasing operational efficiencies, and expanding dosage forms. The company has proposed a dividend of ₹13 crore (₹6.30 per share) for FY26, reflecting confidence in its future potential.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Komal Gupta | Business Upturn

Windlas Biotech reports record Rs 904 crore revenue for FY26 with 19% growth